Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

LRRK2 activation in idiopathic Parkinson's disease.

Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT.

Sci Transl Med. 2018 Jul 25;10(451). pii: eaar5429. doi: 10.1126/scitranslmed.aar5429.

PMID:
30045977
2.

Newly Revised Quantitative PCR-Based Assay for Mitochondrial and Nuclear DNA Damage.

Sanders LH, Rouanet JP, Howlett EH, Leuthner TC, Rooney JP, Greenamyre JT, Meyer JN.

Curr Protoc Toxicol. 2018 May;76(1):e50. doi: 10.1002/cptx.50. Epub 2018 May 18.

PMID:
30040241
3.

Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress.

Van Laar VS, Arnold B, Howlett EH, Calderon MJ, St Croix CM, Greenamyre JT, Sanders LH, Berman SB.

J Neurosci. 2018 Aug 22;38(34):7505-7515. doi: 10.1523/JNEUROSCI.0541-18.2018. Epub 2018 Jul 20.

PMID:
30030401
4.

RAD52 is required for RNA-templated recombination repair in post-mitotic neurons.

Welty S, Teng Y, Liang Z, Zhao W, Sanders LH, Greenamyre JT, Rubio ME, Thathiah A, Kodali R, Wetzel R, Levine AS, Lan L.

J Biol Chem. 2018 Jan 26;293(4):1353-1362. doi: 10.1074/jbc.M117.808402. Epub 2017 Dec 7.

PMID:
29217771
5.

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.

Howlett EH, Jensen N, Belmonte F, Zafar F, Hu X, Kluss J, Schüle B, Kaufman BA, Greenamyre JT, Sanders LH.

Hum Mol Genet. 2017 Nov 15;26(22):4340-4351. doi: 10.1093/hmg/ddx320.

PMID:
28973664
6.

Mitochondrial Complex I Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease.

Milanese C, Tapias V, Gabriels S, Cerri S, Levandis G, Blandini F, Tresini M, Shiva S, Greenamyre JT, Gladwin MT, Mastroberardino PG.

Antioxid Redox Signal. 2018 Jan 1;28(1):44-61. doi: 10.1089/ars.2017.6992. Epub 2017 Sep 21.

PMID:
28816057
7.

Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.

Tapias V, Hu X, Luk KC, Sanders LH, Lee VM, Greenamyre JT.

Cell Mol Life Sci. 2017 Aug;74(15):2851-2874. doi: 10.1007/s00018-017-2541-x. Epub 2017 May 22.

8.

Editor's Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson's Disease Risk.

Sanders LH, Paul KC, Howlett EH, Lawal H, Boppana S, Bronstein JM, Ritz B, Greenamyre JT.

Toxicol Sci. 2017 Jul 1;158(1):188-198. doi: 10.1093/toxsci/kfx086.

9.

Samay Jain, MD, June 2, 1974-September 8, 2016.

Greenamyre JT.

Mov Disord. 2016 Dec;31(12):1800-1801. doi: 10.1002/mds.26852. Epub 2016 Nov 10. No abstract available.

PMID:
27862263
10.

α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease.

Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, Hastings TG, Greenamyre JT.

Sci Transl Med. 2016 Jun 8;8(342):342ra78. doi: 10.1126/scitranslmed.aaf3634.

11.

Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer.

Sahoo B, Arduini I, Drombosky KW, Kodali R, Sanders LH, Greenamyre JT, Wetzel R.

PLoS One. 2016 Jun 6;11(6):e0155747. doi: 10.1371/journal.pone.0155747. eCollection 2016.

12.

Fruit flies, bile acids, and Parkinson disease: a mitochondrial connection?

Greenamyre JT, Sanders LH, Gasser T.

Neurology. 2015 Sep 8;85(10):838-9. doi: 10.1212/WNL.0000000000001912. Epub 2015 Aug 7. No abstract available.

PMID:
26253445
13.

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA.

J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.

14.

LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease.

Tyurina YY, Polimova AM, Maciel E, Tyurin VA, Kapralova VI, Winnica DE, Vikulina AS, Domingues MR, McCoy J, Sanders LH, Bayır H, Greenamyre JT, Kagan VE.

Free Radic Res. 2015 May;49(5):681-91. doi: 10.3109/10715762.2015.1005085. Epub 2015 Mar 5.

15.

Post-status epilepticus treatment with the cannabinoid agonist WIN 55,212-2 prevents chronic epileptic hippocampal damage in rats.

Di Maio R, Cannon JR, Greenamyre JT.

Neurobiol Dis. 2015 Jan;73:356-65. doi: 10.1016/j.nbd.2014.10.018. Epub 2014 Oct 30.

PMID:
25447228
16.

PCR based determination of mitochondrial DNA copy number in multiple species.

Rooney JP, Ryde IT, Sanders LH, Howlett EH, Colton MD, Germ KE, Mayer GD, Greenamyre JT, Meyer JN.

Methods Mol Biol. 2015;1241:23-38. doi: 10.1007/978-1-4939-1875-1_3.

17.

Mitochondrial DNA damage as a peripheral biomarker for mitochondrial toxin exposure in rats.

Sanders LH, Howlett EH, McCoy J, Greenamyre JT.

Toxicol Sci. 2014 Dec;142(2):395-402. doi: 10.1093/toxsci/kfu185. Epub 2014 Sep 18.

18.

Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.

Lee JW, Tapias V, Di Maio R, Greenamyre JT, Cannon JR.

Neurobiol Aging. 2015 Jan;36(1):505-18. doi: 10.1016/j.neurobiolaging.2014.07.011. Epub 2014 Jul 15.

19.

Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.

Sanders LH, McCoy J, Hu X, Mastroberardino PG, Dickinson BC, Chang CJ, Chu CT, Van Houten B, Greenamyre JT.

Neurobiol Dis. 2014 Oct;70:214-23. doi: 10.1016/j.nbd.2014.06.014. Epub 2014 Jun 27.

20.

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.

Schapira AH, Olanow CW, Greenamyre JT, Bezard E.

Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18. Review.

PMID:
24954676
21.

A rapid and sensitive automated image-based approach for in vitro and in vivo characterization of cell morphology and quantification of cell number and neurite architecture.

Tapias V, Greenamyre JT.

Curr Protoc Cytom. 2014 Apr 1;68:12.33.1-22. doi: 10.1002/0471142956.cy1233s68. Review.

PMID:
24692056
22.

Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.

Tapias V, Cannon JR, Greenamyre JT.

Neurobiol Aging. 2014 May;35(5):1162-76. doi: 10.1016/j.neurobiolaging.2013.10.077. Epub 2013 Oct 21.

23.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B.

Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013. Epub 2013 Oct 19.

24.

Automated imaging system for fast quantitation of neurons, cell morphology and neurite morphometry in vivo and in vitro.

Tapias V, Greenamyre JT, Watkins SC.

Neurobiol Dis. 2013 Jun;54:158-68. doi: 10.1016/j.nbd.2012.11.018. Epub 2012 Dec 7.

25.

Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Cannon JR, Geghman KD, Tapias V, Sew T, Dail MK, Li C, Greenamyre JT.

Exp Neurol. 2013 Feb;240:44-56. doi: 10.1016/j.expneurol.2012.11.007. Epub 2012 Nov 12.

26.

DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress.

Mullett SJ, Di Maio R, Greenamyre JT, Hinkle DA.

J Mol Neurosci. 2013 Mar;49(3):507-11. doi: 10.1007/s12031-012-9904-4. Epub 2012 Oct 15.

27.

Thiol oxidation and altered NR2B/NMDA receptor functions in in vitro and in vivo pilocarpine models: implications for epileptogenesis.

Di Maio R, Mastroberardino PG, Hu X, Montero LM, Greenamyre JT.

Neurobiol Dis. 2013 Jan;49:87-98. doi: 10.1016/j.nbd.2012.07.013. Epub 2012 Jul 21.

PMID:
22824136
28.

Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Cannon JR, Greenamyre JT.

Neurobiol Dis. 2013 Sep;57:38-46. doi: 10.1016/j.nbd.2012.06.025. Epub 2012 Jul 7. Review.

29.

Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.

Muñoz P, Paris I, Sanders LH, Greenamyre JT, Segura-Aguilar J.

Biochim Biophys Acta. 2012 Jul;1822(7):1125-36. doi: 10.1016/j.bbadis.2012.03.010. Epub 2012 Mar 27.

30.

Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins.

Milanese C, Sager JJ, Bai Q, Farrell TC, Cannon JR, Greenamyre JT, Burton EA.

J Biol Chem. 2012 Jan 27;287(5):2971-83. doi: 10.1074/jbc.M111.308312. Epub 2011 Nov 29.

31.

Regulation of complex I by Engrailed is complex too.

Sanders LH, Greenamyre JT.

Nat Neurosci. 2011 Sep 27;14(10):1221-2. doi: 10.1038/nn.2939. No abstract available.

PMID:
21952262
32.

The role of environmental exposures in neurodegeneration and neurodegenerative diseases.

Cannon JR, Greenamyre JT.

Toxicol Sci. 2011 Dec;124(2):225-50. doi: 10.1093/toxsci/kfr239. Epub 2011 Sep 13. Review.

33.

Toxin models of mitochondrial dysfunction in Parkinson's disease.

Martinez TN, Greenamyre JT.

Antioxid Redox Signal. 2012 May 1;16(9):920-34. doi: 10.1089/ars.2011.4033. Epub 2011 Jul 12. Review.

34.

Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease.

Jain S, Siegle GJ, Gu C, Moore CG, Ivanco LS, Studenski S, Greenamyre JT, Steinhauer SR.

Mov Disord. 2011 Jun;26(7):1344-7. doi: 10.1002/mds.23628. Epub 2011 Apr 19.

35.

Mouse ES cells overexpressing DNMT1 produce abnormal neurons with upregulated NMDA/NR1 subunit.

D'Aiuto L, Di Maio R, Mohan KN, Minervini C, Saporiti F, Soreca I, Greenamyre JT, Chaillet JR.

Differentiation. 2011 Jul;82(1):9-17. doi: 10.1016/j.diff.2011.03.003. Epub 2011 Apr 13.

36.

Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line.

Paris I, Muñoz P, Huenchuguala S, Couve E, Sanders LH, Greenamyre JT, Caviedes P, Segura-Aguilar J.

Toxicol Sci. 2011 Jun;121(2):376-88. doi: 10.1093/toxsci/kfr060. Epub 2011 Apr 6.

37.

Pilocapine alters NMDA receptor expression and function in hippocampal neurons: NADPH oxidase and ERK1/2 mechanisms.

Di Maio R, Mastroberardino PG, Hu X, Montero L, Greenamyre JT.

Neurobiol Dis. 2011 Jun;42(3):482-95. doi: 10.1016/j.nbd.2011.02.012. Epub 2011 Mar 17.

PMID:
21397025
38.

Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults.

Horowitz MP, Milanese C, Di Maio R, Hu X, Montero LM, Sanders LH, Tapias V, Sepe S, van Cappellen WA, Burton EA, Greenamyre JT, Mastroberardino PG.

Antioxid Redox Signal. 2011 Aug 15;15(4):855-71. doi: 10.1089/ars.2010.3629. Epub 2011 Jun 6.

39.

Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.

Hu X, Weng Z, Chu CT, Zhang L, Cao G, Gao Y, Signore A, Zhu J, Hastings T, Greenamyre JT, Chen J.

J Neurosci. 2011 Jan 5;31(1):247-61. doi: 10.1523/JNEUROSCI.4589-10.2011.

40.

Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson's disease.

Jain S, Siegle GJ, Gu C, Moore CG, Ivanco LS, Jennings JR, Steinhauer SR, Studenski S, Greenamyre JT.

Parkinsonism Relat Disord. 2011 Feb;17(2):119-22. doi: 10.1016/j.parkreldis.2010.11.005. Epub 2010 Nov 27.

41.

Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra.

Cannon JR, Sew T, Montero L, Burton EA, Greenamyre JT.

Exp Neurol. 2011 Mar;228(1):41-52. doi: 10.1016/j.expneurol.2010.10.016. Epub 2010 Nov 5.

42.

Neurotoxic in vivo models of Parkinson's disease recent advances.

Cannon JR, Greenamyre JT.

Prog Brain Res. 2010;184:17-33. doi: 10.1016/S0079-6123(10)84002-6. Review.

PMID:
20887868
43.

Gene-environment interactions in Parkinson's disease: the importance of animal modeling.

Horowitz MP, Greenamyre JT.

Clin Pharmacol Ther. 2010 Oct;88(4):467-74. doi: 10.1038/clpt.2010.138. Epub 2010 Sep 1. Review.

44.

Mitochondrial iron metabolism and its role in neurodegeneration.

Horowitz MP, Greenamyre JT.

J Alzheimers Dis. 2010;20 Suppl 2:S551-68. doi: 10.3233/JAD-2010-100354. Review.

45.

Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents.

Greene JG, Dingledine R, Greenamyre JT.

Neurobiol Dis. 2010 Jun;38(3):476-81. doi: 10.1016/j.nbd.2010.03.014. Epub 2010 Mar 20.

46.

Lessons from the rotenone model of Parkinson's disease.

Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG.

Trends Pharmacol Sci. 2010 Apr;31(4):141-2; author reply 142-3. doi: 10.1016/j.tips.2009.12.006. Epub 2010 Jan 22. Review. No abstract available.

47.

NeuN is not a reliable marker of dopamine neurons in rat substantia nigra.

Cannon JR, Greenamyre JT.

Neurosci Lett. 2009 Oct 16;464(1):14-7. doi: 10.1016/j.neulet.2009.08.023. Epub 2009 Aug 12.

PMID:
19682546
48.

Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.

Tapias V, Cannon JR, Greenamyre JT.

J Neurosci Res. 2010 Feb 1;88(2):420-7. doi: 10.1002/jnr.22201.

PMID:
19681169
49.

Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology.

Drolet RE, Cannon JR, Montero L, Greenamyre JT.

Neurobiol Dis. 2009 Oct;36(1):96-102. doi: 10.1016/j.nbd.2009.06.017. Epub 2009 Jul 10.

PMID:
19595768
50.

A highly reproducible rotenone model of Parkinson's disease.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT.

Neurobiol Dis. 2009 May;34(2):279-90.

Supplemental Content

Loading ...
Support Center